Literature DB >> 7664178

Emergence of a new virulent clone within the electrophoretic type 5 complex of serogroup B meningococci in Norway.

E Wedege1, J Kolberg, A Delvig, E A Høiby, E Holten, E Rosenqvist, D A Caugant.   

Abstract

An increase in B:15:P1.12 meningococci among isolates from patients with Neisseria meningitidis infection in Norway in recent years led to further characterization of such strains. Between 1987 and 1992, B:15:P1.12 strains constituted 9.8% (24 strains) of B:15 isolates. The B:15:P1.12 strains belonged to the electrophoretic type 5 (ET-5) complex, but 17 (71%) strains were a new clone (ET-5c) not found elsewhere in the world. All but one strain of ET-5c were responsible for a localized outbreak of systemic meningococcal disease in western Norway. A novel monoclonal antibody (202,G-12), developed against the unknown variable region 2 on the class 1 protein of one of these strains, bound to 19 of the 15:P1.12 strains, 4 strains bound the subtype P1.13 reference monoclonal antibody MN24H10.75, and the remaining strain showed no reaction. Sequencing of porA genes demonstrated a series of nine threonine residues in the deduced variable region 2 of the latter strain, while four and five threonine residues were found in the corresponding regions of strains reacting with the monoclonal antibodies 202,G-12 and MN24H10.75, respectively. Epitope mapping with synthetic peptides showed that 202,G-12 bound to a sequence of 11 amino acids which included the four threonine residues specific for subtype P1.13a. Immunoglobulin G antibodies against the P1.7,16 subtype protein, induced in volunteers after vaccination with the Norwegian meningococcal vaccine, did not cross-react on immunoblots with the subtype protein of clone ET-5c. Thus, postvaccination class 1 protein antibodies, assumed to be protective, may not be effective against infection with the new clone.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7664178      PMCID: PMC170152          DOI: 10.1128/cdli.2.3.314-321.1995

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  42 in total

1.  Role of horizontal genetic exchange in the antigenic variation of the class 1 outer membrane protein of Neisseria meningitidis.

Authors:  I M Feavers; A B Heath; J A Bygraves; M C Maiden
Journal:  Mol Microbiol       Date:  1992-02       Impact factor: 3.501

2.  Topology of outer membrane porins in pathogenic Neisseria spp.

Authors:  P van der Ley; J E Heckels; M Virji; P Hoogerhout; J T Poolman
Journal:  Infect Immun       Date:  1991-09       Impact factor: 3.441

3.  Bactericidal antibodies after vaccination with the Norwegian meningococcal serogroup B outer membrane vesicle vaccine: a brief survey.

Authors:  E A Høiby; E Rosenqvist; L O Frøholm; G Bjune; B Feiring; H Nøkleby; E Rønnild
Journal:  NIPH Ann       Date:  1991-12

4.  Immunoblotting studies of vaccinee and patient sera from a Norwegian serogroup B meningococcal vaccination trial.

Authors:  E Wedege; G Bjune; L O Frøholm; E A Høiby; E Rosenqvist
Journal:  NIPH Ann       Date:  1991-12

5.  Serotypes and subtypes of Neisseria meningitidis serogroup B strains associated with meningococcal disease in Canada, 1977-1989.

Authors:  F E Ashton; L Mancino; A J Ryan; J T Poolman; H Abdillahi; W D Zollinger
Journal:  Can J Microbiol       Date:  1991-08       Impact factor: 2.419

6.  Construction of a multivalent meningococcal vaccine strain based on the class 1 outer membrane protein.

Authors:  P Van Der Ley; J T Poolman
Journal:  Infect Immun       Date:  1992-08       Impact factor: 3.441

7.  Identification of meningococcal serosubtypes by polymerase chain reaction.

Authors:  M C Maiden; J A Bygraves; J McCarvil; I M Feavers
Journal:  J Clin Microbiol       Date:  1992-11       Impact factor: 5.948

8.  Comparison of the class 1 outer membrane proteins of eight serological reference strains of Neisseria meningitidis.

Authors:  M C Maiden; J Suker; A J McKenna; J A Bygraves; I M Feavers
Journal:  Mol Microbiol       Date:  1991-03       Impact factor: 3.501

9.  Expression of an inaccessible P1.7 subtype epitope on meningococcal class 1 proteins.

Authors:  E Wedege; R Dalseg; D A Caugant; J T Poolman; L O Frøholm
Journal:  J Med Microbiol       Date:  1993-01       Impact factor: 2.472

10.  The Norwegian meningococcal serogroup B outer membrane vesicle vaccine protection trials: case tracing, meningococcal antigen detection and serological diagnosis.

Authors:  E A Høiby; G Bjune; L O Frøholm; J Eng; A Halstensen; E Rosenqvist; E Rønnild; E Wedege
Journal:  NIPH Ann       Date:  1991-12
View more
  12 in total

1.  Molecular epidemiological analysis of the changing nature of a meningococcal outbreak following a vaccination campaign.

Authors:  Liran I Shlush; Doron M Behar; Adrian Zelazny; Nathy Keller; James R Lupski; Arthur L Beaudet; Dani Bercovich
Journal:  J Clin Microbiol       Date:  2002-10       Impact factor: 5.948

2.  Distribution of surface protein variants among hyperinvasive meningococci: implications for vaccine design.

Authors:  Rachel Urwin; Joanne E Russell; Emily A L Thompson; Edward C Holmes; Ian M Feavers; Martin C J Maiden
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

Review 3.  Prospects for vaccine prevention of meningococcal infection.

Authors:  Lee H Harrison
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

4.  Molecular epidemiology of recent belgian isolates of Neisseria meningitidis serogroup B.

Authors:  M Van Looveren; P Vandamme; M Hauchecorne; M Wijdooghe; F Carion; D A Caugant; H Goossens
Journal:  J Clin Microbiol       Date:  1998-10       Impact factor: 5.948

5.  Immune responses against major outer membrane antigens of Neisseria meningitidis in vaccinees and controls who contracted meningococcal disease during the Norwegian serogroup B protection trial.

Authors:  E Wedege; E A Høiby; E Rosenqvist; G Bjune
Journal:  Infect Immun       Date:  1998-07       Impact factor: 3.441

6.  Correlation between serological and sequencing analyses of the PorB outer membrane protein in the Neisseria meningitidis serotyping system.

Authors:  C T Sacchi; A P Lemos; A M Whitney; C A Solari; M E Brandt; C E Melles; C E Frasch; L W Mayer
Journal:  Clin Diagn Lab Immunol       Date:  1998-05

7.  Invasive meningococcal disease in Scotland, 1994 to 1999, with emphasis on group B meningococcal disease.

Authors:  Moe H Kyaw; Stuart C Clarke; Peter Christie; Ian G Jones; Harry Campbell
Journal:  J Clin Microbiol       Date:  2002-05       Impact factor: 5.948

8.  Allelic diversity of the two transferrin binding protein B gene isotypes among a collection of Neisseria meningitidis strains representative of serogroup B disease: implication for the composition of a recombinant TbpB-based vaccine.

Authors:  B Rokbi; G Renauld-Mongenie; M Mignon; B Danve; D Poncet; C Chabanel; D A Caugant; M J Quentin-Millet
Journal:  Infect Immun       Date:  2000-09       Impact factor: 3.441

9.  High case-fatality rates of meningococcal disease in Western Norway caused by serogroup C strains belonging to both sequence type (ST)-32 and ST-11 complexes, 1985-2002.

Authors:  I Smith; D A Caugant; E A Høiby; T Wentzel-Larsen; A Halstensen
Journal:  Epidemiol Infect       Date:  2006-05-02       Impact factor: 2.451

10.  Proposed standardization of Neisseria meningitidis PorA variable-region typing nomenclature.

Authors:  C T Sacchi; A P Lemos; M E Brandt; A M Whitney; C E Melles; C A Solari; C E Frasch; L W Mayer
Journal:  Clin Diagn Lab Immunol       Date:  1998-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.